Effects of NXY-059 in experimental stroke: an individual animal meta-analysis - PubMed (original) (raw)

Meta-Analysis

Effects of NXY-059 in experimental stroke: an individual animal meta-analysis

P M W Bath et al. Br J Pharmacol. 2009 Aug.

Abstract

Background and purpose: Disodium 2,4-disulphophenyl-N-tert-butylnitrone (NXY-059) was neuroprotective in experimental stroke models but ineffective in a large clinical trial. This first-ever individual animal meta-analysis was used to assess the preclinical studies.

Experimental approach: Studies were obtained from AstraZeneca and PubMed searches. Data for each animal were obtained from the lead author of each study and/or AstraZeneca. Published summary data were used if individual data were not available. Infarct volume and motor impairment were standardized to reflect different species and scales. Standardized mean difference (SMD), coefficients from multilevel models and 95% confidence intervals (95% CI) are presented.

Key results: Fifteen studies (26 conditions, 12 laboratories) involving rats (544), mice (9) and marmosets (32) were identified (NXY-059: 332, control: 253) with individual data for 442 animals. Four studies were unpublished. Studies variably used randomization (40%), blinding of surgeon (53%) and outcome assessor (67%). NXY-059 reduced total (SMD -1.17, 95% CI -1.50 to -0.84), cortical (SMD -2.17, 95% CI -2.99 to -1.34) and subcortical (-1.43, 95% CI -2.20 to -0.86) lesion volume; efficacy was seen in transient, permanent and thrombotic ischaemia, up to 180 min post occlusion. NXY-059 reduced motor impairment (SMD -1.66, 95% CI -2.18 to -1.14) and neglect. Evidence for performance, attrition and publication bias was present.

Conclusions and implications: NXY-059 was neuroprotective in experimental stroke although bias may have resulted in efficacy being overestimated. Efficacy in young, healthy, male animals is a poor predictor of clinical outcome. We suggest the use of preclinical meta-analysis before initiation of future clinical trials.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Flow chart of study identification and inclusions and exclusions.

Figure 2

Figure 2

Funnel plot of NXY-059 on total infarct volume incorporating both individual animal data and summary data as assessment of publication bias, Egger et al. (1997) test: P < 0.0001. NXY-059, disodium 2,4-disulphophenyl-N-tert-butylnitrone.

Figure 3

Figure 3

Forest plot of NXY-059 on total infarct volume incorporating both individual animal data and summary data. NXY-059, disodium 2,4-disulphophenyl-N-tert-butylnitrone.

Figure 4

Figure 4

Relationship between study quality and infarct volume, coefficients per 100 mg·kg−1 of total administered NXY-059 dose. NXY-059, disodium 2,4-disulphophenyl-N-tert-butylnitrone.

Figure 6

Figure 6

Relationship between unbound plasma concentration (mg·L−1) and standardized mean difference in infarct volume. Equation of best fit standardized mean difference=−0.13 − 0.02 × unbound plasma concentration (mg·L−1).

Figure 5

Figure 5

Relationship between total plasma concentration and maintenance dose of NXY-059. Equation of best fit [NXY-059]total in plasma (mg·L−1) = 1.57 × maintenance dose (mg·kg−1 h). NXY-059, disodium 2,4-disulphophenyl-N-tert-butylnitrone.

Comment in

Similar articles

Cited by

References

    1. Balogh GT, Vukics K, Konczol A, Kis-Varga A, Gere A, Fischer J. Nitrone derivatives of trolox as neuroprotective agents. Bioorg Med Chem Lett. 2005;15:3012–3015. - PubMed
    1. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986;17:472–476. - PubMed
    1. Crossley NA, Sena E, Goehler J, Horn J, van der Worp B, Bath PMB, et al. Empirical evidence of bias in the design of experimental stroke studies: a meta-epidemiologic approach. Stroke. 2008;39:929–934. - PubMed
    1. Diener HC, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke. 2008;39:1751–1758. - PubMed
    1. Edenius C, Strid S, Borga O, Breitholtz-Emanuelsson A, Lanbeck Vallén K, Fransson B. Pharmacokinetics of NXY-059, a nitrone-based free radical trapping agent, in health young and eldery subjects. J Stroke Cerebrovasc Dis. 2002;11:34–43. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources